The goal of the High Speed Cell Sorter (HSCS) Core is to provide outstanding cell sorting and analysis service for SCC members. Flow cytometry is an essential tool for basic and translational cancer research. The analytical and preparative platforms in this Core are used to quantify, characterize, and purify cellular populations of interest for in vitro and in vivo studies by Core users. The HSCS Core was established in 2001 and has experienced rapid growth in capacity and utilization over a short period of time.
The Aims of the HSCS Core are as follows:
Aim 1. To develop and maintain flexible platforms for multiparameter cell analysis. Four 5-color and one 8-color benchtop flow cytometric analyzers are available 24/7 for use by cancer center members. Three cell sorters operated by Core staff support more sophisticated analysis involving up to 20 parameters.
Aim 2. To develop and maintain flexible platforms for multiparameter cell sorting. Three cell sorters provide a highly customizable platform that can support high speed sorting on up to 10 simultaneous parameters. Workflow is separated within the Core into three distinct domains for sorting of cells from humans, model organisms, or from potentially biohazardous samples.
Aim 3. To provide additional services that enhance the academic mission of the SCC. The HSCS Core will promote the use of flow cytometry in cancer-related research by providing technical assistance in preparation of cells for sorting or analysis, training personnel on use of flow cytometry instrumentation, and assisting with data archiving, analysis, interpretation, grant writing, and manuscript preparation.
The High Speed Cell Sorter Core uses state-of-the-art instrumentation and highly trained personnel to assist scientists with cell measurements and manipulations that are essential for modern research in cancer biology.
|Abboud, Ramzi; Keller, Jesse; Slade, Michael et al. (2016) Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. Biol Blood Marrow Transplant 22:1851-60|
|Johnson, Kimberly J; Zoellner, Nancy L; Gutmann, David H (2016) Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol 42:53-9|
|Zuiani, Adam; Chen, Kevin; Schwarz, Megan C et al. (2016) A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. J Virol 90:10499-10512|
|Chou, Chun; Verbaro, Daniel J; Tonc, Elena et al. (2016) The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses. Immunity 45:570-82|
|Durai, Vivek; Murphy, Kenneth M (2016) Functions of Murine Dendritic Cells. Immunity 45:719-736|
|Brownson, Ross C; Dodson, Elizabeth A; Kerner, Jon F et al. (2016) Framing research for state policymakers who place a priority on cancer. Cancer Causes Control 27:1035-41|
|Mertins, Philipp; Mani, D R; Ruggles, Kelly V et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534:55-62|
|Niu, Haixia; Hadwiger, Gayla; Fujiwara, Hideji et al. (2016) Pathways of retinoid synthesis in mouse macrophages and bone marrow cells. J Leukoc Biol 99:797-810|
|Beeman, Scott C; Shui, Ying-Bo; Perez-Torres, Carlos J et al. (2016) O2 -sensitive MRI distinguishes brain tumor versus radiation necrosis in murine models. Magn Reson Med 75:2442-7|
|Fehniger, Todd A; Cooper, Megan A (2016) Harnessing NK Cell Memory for Cancer Immunotherapy. Trends Immunol 37:877-888|
Showing the most recent 10 out of 947 publications